Trial Profile
A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat administered once daily versus twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2015
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis Pharma
- 25 Apr 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
- 21 Jun 2012 Additional company (Boehringer Ingelheim) added in association as reported by European Clinical Trials Database.
- 06 Aug 2011 This trial is recruiting in France and has completed in Great Britain.